Zysthera is developing next generation immunotherapy for bladder cancer.
A worldwide Bacillus Calmette-Guérin shortage of 15-20% (1) is impacting approx. 30’000 bladder cancer patients per year for 10 years now.
This has resulted in:
2.9 times higher risk of recurrence (2)
4.7 times higher rate of cystectomy (2)
3.8 times higher costs (2)
(1) Harvey et al, Urol Oncol 2022
(2) Ourfali et al, Eur Urol Focus 2021
Members of ZYSTHERA have co-developed the clinical implementation of a new immunotherapeutic for the treatment of bladder cancer. ZYSTHERA aims to initiate phase III studies with the aim to close the Bacillus Calmette-Guérin shortage as soon as possible.
Details to follow...
Bladder cancer is one of the most common cancer types.
Every year it impacts the lives of 575'000 patients. 200’000 patients die every year. The shortage of Bacillus Calmette-Guérin is impacting these patients that could live longer.